{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:40:45Z","timestamp":1780087245229,"version":"3.54.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Prostate-specific membrane antigen (PSMA)-targeted PET\/CT has become increasingly important in the management of prostate cancer, especially in localization of biochemical recurrence (BCR). PSMA-targeted PET\/CT imaging with long-lived radionuclides as <jats:sup>89<\/jats:sup>Zr (T<jats:sub>1\/2<\/jats:sub>\u2009=\u200978.4\u00a0h) may improve diagnostics by allowing data acquisition on later time points. In this study, we present our first clinical experience including preliminary biodistribution and dosimetry data of [<jats:sup>89<\/jats:sup>Zr]Zr-PSMA-617 PET\/CT in patients with BCR of prostate cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Seven patients with BCR of prostate cancer who revealed no (<jats:italic>n<\/jats:italic>\u2009=\u20094) or undetermined (<jats:italic>n<\/jats:italic>\u2009=\u20093) findings on [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT imaging were referred to [<jats:sup>89<\/jats:sup>Zr]Zr-PSMA-617 PET\/CT. PET\/CT imaging was performed 1\u00a0h, 24\u00a0h, 48\u00a0h, and 72\u00a0h post injection (p.i.) of 111\u2009\u00b1\u200911\u00a0MBq [<jats:sup>89<\/jats:sup>Zr]Zr-PSMA-617 (mean\u2009\u00b1\u2009standard deviation). Normal organ distribution and dosimetry were determined. Lesions visually considered as suggestive of prostate cancer were quantitatively analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Intense physiological uptake was observed in the salivary and lacrimal glands, liver, spleen, kidneys, intestine and urinary tract. The parotid gland received the highest absorbed dose (0.601\u2009\u00b1\u20090.185\u00a0mGy\/MBq), followed by the kidneys (0.517\u2009\u00b1\u20090.125\u00a0mGy\/MBq). The estimated overall effective dose for the administration of 111\u00a0MBq was 10.1\u00a0mSv (0.0913\u2009\u00b1\u20090.0118\u00a0mSv\/MBq). In 6 patients, and in particular in 3 of 4 patients with negative [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT, at least one prostate cancer lesion was detected in [<jats:sup>89<\/jats:sup>Zr]Zr-PSMA-617 PET\/CT imaging at later time points. The majority of tumor lesions were first visible at 24\u00a0h p.i. with continuously increasing tumor-to-background ratio over time. All tumor lesions were detectable at 48\u00a0h and 72\u00a0h p.i.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>[<jats:sup>89<\/jats:sup>Zr]Zr-PSMA-617 PET\/CT imaging is a promising new diagnostic tool with acceptable radiation exposure for patients with prostate cancer especially when [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT imaging fails detecting recurrent disease. The long half-life of <jats:sup>89<\/jats:sup>Zr enables late time point imaging (up to 72\u00a0h in our study) with increased tracer uptake in tumor lesions and higher tumor-to-background ratios allowing identification of lesions non-visible on [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT imaging.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-022-05925-3","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T04:05:46Z","timestamp":1659672346000},"page":"4736-4747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["[89Zr]Zr-PSMA-617 PET\/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates"],"prefix":"10.1007","volume":"49","author":[{"given":"Florian","family":"Rosar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schaefer-Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bartholom\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Petto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Burgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan M.","family":"Priv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben M.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne H. W.","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nagarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Khreish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-3375","authenticated-orcid":false,"given":"Samer","family":"Ezziddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"key":"5925_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ucl.2018.03.016","volume":"45","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Iravani A, Nzenza T, Murphy DG. Advances in urologic imaging: prostate-specific membrane antigen ligand PET imaging. Urol Clin North Am. 2018;45:503\u201324.","journal-title":"Urol Clin North Am"},{"key":"5925_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcb.10661","volume":"91","author":"A Ghosh","year":"2004","unstructured":"Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91:528\u201339.","journal-title":"J Cell Biochem"},{"key":"5925_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","volume":"58","author":"SM Schwarzenboeck","year":"2017","unstructured":"Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, et al. PSMA ligands for PET imaging of prostate cancer. J Nucl Med. 2017;58:1545\u201352.","journal-title":"J Nucl Med"},{"key":"5925_CR4","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M. 177Lu-PSMA Radioligand therapy for prostate cancer. J Nucl Med. 2017;58:1196\u2013200.","journal-title":"J Nucl Med"},{"key":"5925_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00259-019-04524-z","volume":"47","author":"W Cytawa","year":"2020","unstructured":"Cytawa W, Seitz AK, Kircher S, Fukushima K, Tran-Gia J, Schirbel A, et al. 68Ga-PSMA I&T PET\/CT for primary staging of prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:168\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5925_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.euo.2021.01.007","volume":"4","author":"L Valle","year":"2021","unstructured":"Valle L, Shabsovich D, de Meerleer G, Maurer T, Murphy DG, Nickols NG, et al. Use and impact of positron emission tomography\/computed tomography prior to salvage radiation therapy in men with biochemical recurrence after radical prostatectomy: a scoping review. Eur Urol Oncol. 2021;4:339\u201355.","journal-title":"Eur Urol Oncol"},{"key":"5925_CR7","first-page":"596","volume":"62","author":"A Farolfi","year":"2021","unstructured":"Farolfi A, Calderoni L, Mattana F, Mei R, Telo S, Fanti S, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med Off Publ Soc Nucl Med. 2021;62:596\u2013604.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"5925_CR8","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","volume":"49","author":"F Rosar","year":"2022","unstructured":"Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, et al. Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2022;49:1584\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5925_CR9","doi-asserted-by":"publisher","first-page":"79S","DOI":"10.2967\/jnumed.115.170720","volume":"57","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57:79S-89S.","journal-title":"J Nucl Med"},{"key":"5925_CR10","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.3390\/cancers13246255","volume":"13","author":"OC Neels","year":"2021","unstructured":"Neels OC, Kopka K, Liolios C, Afshar-Oromieh A. Radiolabeled PSMA inhibitors. Cancers. 2021;13:6255.","journal-title":"Cancers"},{"key":"5925_CR11","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5925_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer. JAMA Oncol. 2019;5:856\u201363.","journal-title":"JAMA Oncol"},{"key":"5925_CR13","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2967\/jnumed.119.238071","volume":"61","author":"M Beheshti","year":"2020","unstructured":"Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, et al. Multiphasic 68Ga-PSMA PET\/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1 ng\/mL: a prospective study of 135 patients. J Nucl Med. 2020;61:1484\u201390.","journal-title":"J Nucl Med"},{"key":"5925_CR14","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00259-021-05189-3","volume":"48","author":"A Afshar-Oromieh","year":"2021","unstructured":"Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [68Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging. 2021;48:2925\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5925_CR15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"5925_CR16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5925_CR17","first-page":"362","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of 18F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med Off Publ Soc Nucl Med. 2019;60:362\u20138.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"5925_CR18","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.3390\/ijms21124309","volume":"21","author":"J-K Yoon","year":"2020","unstructured":"Yoon J-K, Park B-N, Ryu E-K, An Y-S, Lee S-J. Current perspectives on 89Zr-PET imaging. Int J Mol Sci. 2020;21:4309.","journal-title":"Int J Mol Sci"},{"key":"5925_CR19","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1021\/acs.bioconjchem.7b00325","volume":"28","author":"S Heskamp","year":"2017","unstructured":"Heskamp S, Raav\u00e9 R, Boerman O, Rijpkema M, Goncalves V, Denat F. 89Zr-Immuno-positron emission tomography in oncology: state-of-the-art 89Zr radiochemistry. Bioconjug Chem. 2017;28:2211\u201323.","journal-title":"Bioconjug Chem"},{"key":"5925_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2967\/jnumed.120.250720","volume":"62","author":"K-H Jung","year":"2021","unstructured":"Jung K-H, Park JW, Lee JH, Moon SH, Cho YS, Lee K-H. 89Zr-labeled anti-PD-L1 antibody PET monitors gemcitabine therapy-induced modulation of tumor PD-L1 expression. J Nucl Med. 2021;62:656\u201364.","journal-title":"J Nucl Med"},{"key":"5925_CR21","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2967\/jnumed.119.239558","volume":"62","author":"GAMS van Dongen","year":"2021","unstructured":"van Dongen GAMS, Beaino W, Windhorst AD, Zwezerijnen GJC, Oprea-Lager DE, Hendrikse NH, et al. The role of 89Zr-immuno-PET in navigating and derisking the development of biopharmaceuticals. J Nucl Med. 2021;62:438\u201345.","journal-title":"J Nucl Med"},{"key":"5925_CR22","first-page":"2309","volume":"8","author":"DN Pandya","year":"2017","unstructured":"Pandya DN, Bhatt N, Yuan H, Day CS, Ehrmann BM, Wright M, et al. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development. Chem Sci The Royal Society of Chemistry. 2017;8:2309\u201314.","journal-title":"Chem Sci The Royal Society of Chemistry"},{"key":"5925_CR23","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1007\/s00259-021-05661-0","volume":"49","author":"BM Priv\u00e9","year":"2022","unstructured":"Priv\u00e9 BM, Derks YHW, Rosar F, Franssen GM, Peters SMB, Khreish F, et al. 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. Eur J Nucl Med Mol Imaging. 2022;49:2064\u201376.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"5925_CR24","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1109\/TMI.2008.2012036","volume":"28","author":"M Hatt","year":"2009","unstructured":"Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D. A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. IEEE Trans Med Imaging. 2009;28:881\u201393.","journal-title":"IEEE Trans Med Imaging."},{"key":"5925_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","volume":"7","author":"M Andersson","year":"2017","unstructured":"Andersson M, Johansson L, Eckerman K, Mattsson S. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms. EJNMMI Res. 2017;7:88.","journal-title":"EJNMMI Res."},{"key":"5925_CR26","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1088\/0031-9155\/57\/14\/4501","volume":"57","author":"M Zankl","year":"2012","unstructured":"Zankl M, Schlattl H, Petoussi-Henss N, Hoeschen C. Electron specific absorbed fractions for the adult male and female ICRP\/ICRU reference computational phantoms. Phys Med Biol. 2012;57:4501\u201326.","journal-title":"Phys Med Biol"},{"key":"5925_CR27","first-page":"1","volume":"39","author":"H-G Menzel","year":"2009","unstructured":"Menzel H-G, Clement C, DeLuca P. ICRP Publication 110. Realistic reference phantoms: an ICRP\/ICRU joint effort. A report of adult reference computational phantoms. Ann ICRP. 2009;39:1\u2013164.","journal-title":"Ann ICRP."},{"key":"5925_CR28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0146-6453(02)00021-0","volume":"32","author":"ICRP","year":"2002","unstructured":"ICRP. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2002;32:5\u2013265.","journal-title":"Ann ICRP."},{"key":"5925_CR29","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697\u2013705.","journal-title":"J Nucl Med"},{"key":"5925_CR30","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","volume":"43","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Hetzheim H, K\u00fcbler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5925_CR31","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Bene\u0161ov\u00e1 M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57:1170\u20136.","journal-title":"J Nucl Med"},{"key":"5925_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:42\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5925_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2967\/jnumed.121.262290","volume":"63","author":"F Dietlein","year":"2022","unstructured":"Dietlein F, Kobe C, V\u00e1zquez SM, Fischer T, Endepols H, Hohberg M, et al. An 89Zr-labeled PSMA tracer for PET\/CT imaging of prostate cancer patients. J Nucl Med. 2022;63:573\u201383.","journal-title":"J Nucl Med"},{"key":"5925_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/RLU.0000000000004108","volume":"47","author":"F Rosar","year":"2022","unstructured":"Rosar F, Bartholom\u00e4 M, Maus S, Priv\u00e9 BM, Khreish F, Franssen GM, et al. 89Zr-PSMA-617 PET\/CT may reveal local recurrence of prostate cancer unidentified by 68Ga-PSMA-11 PET\/CT. Clin Nucl Med. 2022;47:435\u20136.","journal-title":"Clin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05925-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05925-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T04:14:23Z","timestamp":1666757663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05925-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["5925"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05925-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the patients described herein were in accordance with the ethical standards of the Institutional and\/or National Research Ethics Committees and with the 1964 Helsinki Declaration and its later amendments, or with comparable ethical standards. Approval of our ethics committee was waived due to the retrospective nature of the scientific analysis. This report does not include any animal studies.\u00a0Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients have given written consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}